The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy.
Editor's Note: This article originally appeared on Abbott's website.
ABBOTT PARK, Ill., July 27, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle® Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with high accuracy. This approval makes Abbott's revolutionary continuous glucose monitor (CGM) the longest lasting self-applied personal glucose sensor available on the market.
"At Abbott, we are continuously pushing for new innovations that minimize the daily burden of managing diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "With the new FreeStyle Libre 14 day system, people with diabetes will now have extended access to their glucose data with a high degree of accuracy, which will improve their experience and help empower them to better manage their condition." Click here to continue>>
News from our partners